HHS Assistant Secretary of Public Affairs Tom Corry unexpectedly stepped down on Feb. 28. In a brief post on X Monday morning ...

The US Food and Drug Administration (FDA) has accepted for review GSK’s Biologics License Application for depemokimab.

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations ...

NEW YORK CITY, NY / ACCESS Newswire / March 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...